key: cord-0698947-wk899k9l authors: Cherian, Robin; Chandra, Bharatendu; Tung, Moon Ley; Vuylsteke, Alain title: COVID-19 conundrum: Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness date: 2020-07-16 journal: Eur Respir J DOI: 10.1183/13993003.02135-2020 sha: 678e186fa17ec2404314e821435f2d460ce1260e doc_id: 698947 cord_uid: wk899k9l The current evidence of COVID-19 pathophysiology supports the idea of specific phenotypes, and clinical phenotyping may be valuable to guide therapy. Twitter: The current evidence of COVID-19 pathophysiology supports the idea of specific phenotypes, and clinical phenotyping may be valuable to guide therapy. We read with interest the recent editorial by Bos et al on the perils of premature phenotyping in COVID-19 [1] . The authors concluded that a normal compliance variant of ARDS does not exist, based on two small cohort studies reporting low respiratory system compliance in COVID-19 patients [2, 3] . However, this assumption may be erroneous, as first, the admission and intubation thresholds are highly variable across units, resulting in marked heterogeneity. Secondly, several studies demonstrate that a high proportion of mechanically ventilated COVID-19 patients exhibit near-normal lung compliance [4] [5] [6] . These observations, on first glance, seem incompatible with the current understanding of ARDS pathophysiology, as profound hypoxemia and normal lung compliance rarely co-exist in ARDS [7] . A heuristic approach would be to ignore these inconsistencies, attempting to 'fit' them into existing paradigms. However, initial intuitions may often be wrong, and cognitive biases must be overcome to find a solution to this conundrum. Using a deductive approach, firstly the diagnostic criteria need a relook, to exclude misclassification as a reason for the observed clinico-pathological discrepancy. ARDS is characterized by diffuse alveolar damage (DAD), with increased pulmonary vascular permeability, loss of aerated lung tissue and low respiratory system compliance [8] . However, several unrelated pathologies such as eosinophilic pneumonia or diffuse alveolar haemorrhage may cause respiratory failure fulfilling the clinical criteria for ARDS [9] . Accordingly, these ARDS mimics [9] require specific treatment based on their underlying pathophysiology. Several other conditions presenting with hypoxemia and normal lung compliance may additionally be misclassified as ARDS; diffuse microvascular pulmonary thrombosis being one such pathology. In a case report [10] , the clinical presentation was 'ARDS-like', with profound hypoxemia and bilateral infiltrates on radiology, but with normal ventilatory parameters on spirometry. Such disorders, where perfusion impairment is the dominant mechanism for hypoxemia, cannot be considered as 'true' ARDS [6] . This lack of diagnostic specificity of the Berlin definition could be due to the omission of objective indicators of lung volume loss, such as low respiratory system compliance, in its final version [8] . The early radiological changes of ground glassing and consolidation in COVID-19 were considered to be infective or inflammatory in aetiology [11] . However, recent paired parenchymalperfusion imaging studies demonstrate well-demarcated perfusion defects underlying these changes, implicating a thrombotic aetiology [4, [12] [13] [14] [15] [16] . Unmatched defects are also seen [4, 15] . Moreover, the parenchymal changes follow a peripheral 'vascular distribution' which are often wedge-shaped [11, 16] . These findings suggest that the primary insult is vaso-occlusive, as infections or inflammation are rarely confined to vascular boundaries. Additionally, proximal vascular dilatation suggests distal vessel occlusion [13, 16] Interestingly, rapid radiological resolution and clinical improvement with inhaled thrombolytics have been described in a small case series [17] . Autopsy findings of viral endotheliitis, further clarify the pathogenesis of thrombotic manifestations in COVID-19 [18, 19] with a prothrombotic cytokine response [20] that mirrors the response seen in extensive vascular injury [21] . Further, natural and iatrogenic sequelae could explain the observed phenotypic heterogeneity of COVID-19 [5, 7] (Figure 1 ). Of note, DAD is not universally found on autopsies [22] , suggesting this as a sequela and the terminal pathology than the index event. On the other hand, diffuse pulmonary microthrombosis is consistently visible on autopsies. [18, 22, 23] . The early COVID-19 respiratory failure phenotype, with hypoxemia in the presence of preserved lung mechanics [4] [5] [6] suggests perfusion impairments as the main pathophysiology. Although the ground glass changes signify ventilatory impairments, owing to perfusion loss, the affected alveoli act as dead spaces rather than shunts. In this situation, hypoxemia occurs primarily due to flow redistribution and overperfusion involving a significantly reduced vascular bed resulting in ventilation/perfusion mismatch [24, 25] . This typically requires loss of 40 to 50 percent of pulmonary vascular bed before clinically significant hypoxemia could occur, indicating a large reserve. Reduced mixed venous saturation could further exacerbate hypoxemia. Also, during extensive obstruction, available time for red cell oxygenation within the alveolar capillaries may be reduced, due to insufficient microcirculatory recruitment and increased flow velocities. Diffusion limitation may result, further aggravating hypoxemia [24, 25] . These insights are key to understanding the clinical phenotypes of COVID-19 lung injury. While hypoxemia can result either from ventilatory impairments or from disorders of alveolar perfusion, there are stark differences in their clinical features. In alveolar diseases such as pneumonia, shunt perfusion results in early hypoxemia, with clinically proportionate dyspnea due to abnormal lung compliance. However, in progressive perfusion loss, hypoxemia manifests late due to the large lung perfusion reserve, initial ventilatory compensation that mitigates ventilation/perfusion mismatch from overperfusion, and adequate initial right ventricular compensation to acute pressure overload. Further, unlike ventilatory disorders, the initial hypoxemia in this situation may be 'silent' owing to minimal parenchymal injury and normal lung compliance, at this stage. However, once dyspnea sets in, there would be rapid clinical progression whereby minor changes in mixed venous saturations or transit time could result in major changes in systemic oxygen saturation. Correspondingly, as the perfusion reserve continues to decline, physiological stress and exertion would be poorly tolerated. Eventually, right heart compromise would result in cardio-respiratory collapse and rapidly progressing multi-organ failure. Although COVID-19 respiratory failure may fulfil the Berlin criteria, it would be inappropriate to describe the early lung pathology of progressive pulmonary in-situ thrombosis as ARDS. Evidence-based therapies for ARDS may not be applicable at this stage of illness as the lung mechanics and hemodynamics mirror that of a large pulmonary embolism. Moreover, a protocolbased 'one size fits all' approach could potentially be catastrophic, as employing a high positive endexpiratory pressure strategy in a normally compliant lung would result in significant barotrauma and deterioration of right heart dysfunction. As lung pathology appears grossly different at various stages of illness, a tailored phenotypic approach to management, guided by pathophysiology, would be more appropriate than a syndromic approach. The perils of premature phenotyping in COVID: a call for caution Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019: Critical Care Medicine Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers COVID-19 Does Not Lead to a "Typical COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med Acute Respiratory Distress Syndrome: The Berlin Definition Acute respiratory distress syndrome. Nat Rev Dis Primers Diffuse microvascular pulmonary thrombosis associated with primary antiphospholipid antibody syndrome Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. The Lancet Infectious Diseases CONTRAST-ENHANCED Ultrasound in Patients With COVID -19: Pneumonia, Acute Respiratory Distress Syndrome, or Something Else? Are diseaserelated pulmonary perfusion abnormalities detectable in COVID-19 patients? Suspicious findings in a lung perfusion SPECT performed for ruling out classical pulmonary embolism Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Endothelial cell infection and endotheliitis in COVID-19. The Lancet Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. The Lancet Rheumatology Hemorrhage and resuscitation induce alterations in cytokine expression and the development of acute lung injury Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective Gas exchange and ventilation-perfusion relationships in the lung The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases